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Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly
effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products
of which contribute to the conservative homologous recombination repair of DNA double-strand breaks. Nonetheless,
several setbacks in clinical trial settings have highlighted some of the issues surrounding the investigation of PARP
inhibitors, especially the identification of patients who stand to benefit from such drugs. One potential approach to
finding this patient subpopulation is to examine the tumor DNA for evidence of a homologous recombination defect.
However, although the genomes of many breast and ovarian cancers are replete with aberrations, the presence of
numerous factors able to shape the genomic landscape means that only some of the observed DNA abnormalities are
the outcome of a cancer cell’s inability to faithfully repair DNA double-strand breaks. Consequently, recently developed
methods for comprehensively capturing the diverse ways in which homologous recombination deficiencies may arise
beyond BRCA1/2 mutation have used DNA microarray and sequencing data to account for potentially confounding
features in the genome. Scores capturing telomeric allelic imbalance, loss of heterozygosity (LOH) and large scale
transition score, as well as the total number of coding mutations are measures that summarize the total burden of
certain forms of genomic abnormality. By contrast, other studies have comprehensively catalogued different types of
mutational pattern and their relative contributions to a given tumor sample. Although at least one study to explore the
use of the LOH scar in a prospective clinical trial of a PARP inhibitor in ovarian cancer is under way, limitations that
result in a relatively low positive predictive value for these biomarkers remain. Tumors whose genome has undergone
one or more events that restore high-fidelity homologous recombination are likely to be misclassified as double-strand
break repair-deficient and thereby sensitive to PARP inhibitors and DNA damaging chemotherapies as a result of prior
repair deficiency and its genomic scarring. Therefore, we propose that integration of a genomic scar-based biomarker
with a marker of resistance in a high genomic scarring burden context may improve the performance of any
companion diagnostic for PARP inhibitors.Introduction
Cancer is a disease of the genome. In certain types of
cancers, a handful of mutations drive and accompany
carcinogenesis; in others, tumor growth unfolds in the
context of widespread genomic turmoil [1]. The latter
scenario is the consequence of the tumor securing a
mutator phenotype in which one or more of the mecha-
nisms that preserve genomic integrity are undermined.
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furnishes the genetic variation that is grist to the mill of
natural selection [2]. Immune responses, anti-growth
signaling, and competition for space and resources all
contribute to the selection of cancer cell clones with the
fitness advantage to proliferate and dominate the tumor
landscape [3].
Unearthing the information buried within cancer
genomes will have two consequences for the management
of cancer in the clinic. On the one hand, identification of
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oncogenic pathway. On the other hand, tracing scars in a
patient’s tumor genome back to particular drivers of the
mutator phenotype that caused them will enable the selec-
tion of treatments that target these origins. In this review,
we will focus on the latter application and, in particular, on
how the genomic scars that are carved out by a deficiency
in a DNA repair process known as homologous recombin-
ation (HR) may be measured and used as biomarkers or
companion diagnostics for response to platinum-based
chemotherapies and synthetic lethal agents such as the poly
(ADP-ribose) polymerase (PARP) inhibitors.The need for a companion diagnostic based on
homologous recombination deficiency
Familial mutations in one copy of either the BRCA1 or
BRCA2 gene predispose patients to female breast (85%
lifetime risk), ovarian (10% to 40%), male breast, pancreatic,
or prostate cancer [4]. The majority of breast tumors that
develop in carriers of BRCA1 mutations - the products of
which are involved in HR - are triple-negative breast can-
cers (TNBCs) overlapping with the gene expression-defined
subtype of breast cancer known as ‘basal-like breast cancer’,
whereas BRCA2 mutation-associated breast cancers have a
less restricted immunohistochemical phenotype [5-7]. As a
result of the BRCA1/2-related deficiency in HR, pre-
cancerous cells within at-risk organs are unable to reliably
repair DNA double-strand breaks [8], resulting in genomic
instability that eventually leads to cancer. These tumors are
intrinsically sensitive to DNA damage response inhibitors,
such as the PARP inhibitors, whose putative efficacy lever-
ages upon a synthetic lethal effect [9] in which cell death
results from mutations in two or more genes but not in
each gene individually (reviewed in [10]). This phenomenon
is well illustrated by PARP inhibition in BRCA1/2-deficient
cells whereby PARP-dependent base excision repair and
replication fork maintenance functions become critical to
cell viability.
Elegant preclinical work by Bryant and colleagues [11]
and Farmer and colleagues [12] demonstrating the increased
sensitivity of BRCA1/2-deficient cells to PARP inhibition
and the subsequent resistance to PARP inhibition on restor-
ation of BRCA2 functionality provided the impetus for the
use of PARP inhibitors in patients with BRCA1/2-associated
cancers and subsequently in sporadic cancers that display
‘BRCAness’ (that is, have defective HR without germline
BRCA1/2 mutations) [13]. BRCAness can be explained by
epigenetic silencing of BRCA1/2 or the inactivation of
several other HR-associated genes such as PTEN, ATM,
ATR, AURA, PALB2, BRIP, and RAD51 and the FANC
family of genes [14-18]. These have been associated with
several malignancies, including TNBC and sporadic high-
grade serous ovarian cancer (HGSC).Despite the early success of PARP inhibitors in demon-
strating efficacy and a favorable toxicity profile in the treat-
ment of previously heavily treated hereditary BRCA1/2-
related breast and ovarian cancers [19-22], trials that
expanded to include patients without BRCA1/2 mutations
were less successful. Clinical features considered surrogates
for BRCAness within these trials (for example, TNBC or
HGSC) might not have been sufficiently specific in predict-
ing response to PARP inhibitors. Indeed, 50% of HGSCs
are thought to be HR-deficient [23].
Recent recognition that iniparib (also known as BSI-201
or SAR240550) from BiPar/Sanofi (formerly Sanofi-Aventis,
Paris, France) was erroneously considered a PARP inhibitor
during its clinical evaluation within a phase III trial [24,25],
and new phase I and II data reporting on the anti-tumor
activity of various potent PARP inhibitors such as niraparib
(MK4827) [26], BMN673 [27], and rucaparib [28] in
BRCA1/2-mutated tumors and sporadic HGSC, non-small-
cell lung cancer, prostate cancer, and pancreatic cancer, have
renewed enthusiasm for PARP inhibitor drug development.
Therefore, the challenge remains to develop an efficient and
coordinated strategy to identify effective biomarkers such
that the patients who are more likely to respond to drugs
like the PARP inhibitors may be identified. The complexity
of the crosstalk between DNA repair pathways suggests that
assays that detect the status of multiple DNA repair path-
ways could prove critical for PARP inhibitor biomarker
development.
Genomic aberrations in cancer
The majority of TNBCs and HGSCs exhibit a high burden
of genomic aberration. High-throughput genomic technol-
ogy such as next-generation sequencing and DNA micro-
arrays have made it possible to construct comprehensive
catalogues that illustrate the complexity of such changes in
those cancers. Commonly used classifications of genomic
aberrations address the size and type of variation in DNA
sequence (Figure 1). Mutations encompass substitutions,
insertions, and deletions (collectively termed ‘indels’) that
affect one or a few nucleotide bases. Depending on the
location of the mutation, either the amount (mutation in a
regulatory region) or the sequence (non-synonymous cod-
ing mutation) of a gene product may be affected; in either
case, the impact on a protein’s function is the primary inter-
est. Conversely, the significance of mutations irrespective of
their genomic location lies with the processes by which they
were generated [29,30]. Structural aberrations are oper-
ationally defined as acquired changes that exceed 1 Kbp in
size. In general, two fundamental types are discernible: (a)
regional copy number aberrations (CNAs), which are
delineated by a gain or loss in the number of copies of a de-
fined, subchromosomal region of DNA; and (b) structural
rearrangements, which are defined by a change to the
precise location or orientation of a given sequence of DNA.
Figure 1 Genomic aberrations in cancer. Three classes of genomic aberration that develop in cancer cells are depicted: mutations of less than 1
Kbp in length (top box), structural copy number aberrations (CNAs) (bottom left box), and structural rearrangements (bottom right box). The initial
state in the germline is shown followed by the corresponding change in the tumor. Mutations that affect regions of less than 1 Kbp are of three basic
types: substitutions, of which there are transversions and transitions; insertions; and deletions. Insertions and deletions are often collectively termed
‘indels’. Structural CNAs are typically greater than 1 Kbp in size. One of the basic types is copy number gain. The two homologous chromosomes are
shown with a gain of two further copies of region A on the paternal chromosome leading to an imbalance in the allelic ratio (1:3, maternal: paternal).
The gained region is highlighted by the green bar adjacent to paternal region A. Copy number loss of regions A and B on the paternal chromosome
is shown with a red bar highlighting the deleted regions. Three of the commonest types of structural rearrangement are shown, with the letters A to
D and X to Z depicting defined chromosomal segments. An inversion on the same chromosome results in a change to the orientation of DNA
sequences on the same chromosome either paracentrically (without crossing the centromere) or pericentrically (crossing the centromere). The
inverted sequences in the tumor are shown in red. Translocations can be reciprocal or non-reciprocal and typically occur between non-homologous
chromosomes (the green and blue chromosomes are non-homologous). A reciprocal translocation is shown with regions A and B exchanged for
regions X and Y. Recombinations typically occur between sister chromatids where they are conservative, but can occur between homologous
chromosomes (the green and purple chromosomes are homologous with green being the maternal, and purple the paternal) where recombinations
at a heterozygous allelic locus can lead to cnLOH. The dotted boxes indicate where these aberrations are detectable by single-nucleotide polymorphism
microarrays, whereas the grey dashed line encompasses those that can also be captured by array comparative genomic hybridization (aCGH), which does
not distinguish between alleles. All forms of aberration may be interrogated by using sequencing. A, adenine; C, cytosine; cnLOH, copy number-neutral loss
of heterozygosity; G, guanine; LOH, loss of heterozygosity; T, thymine.
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non-homologous regions of DNA), inversions (a change to
the orientation of a defined sequence of DNA), and recom-
binations (most often used to express the exchange of
material between homologous regions of DNA) are the
most frequently described [31]. The potential outcome of
this latter structural rearrangement is that of regional loss
of heterozygosity (LOH), in which one of the parental cop-
ies of a heterozygous region of DNA is lost and the other
retained. LOH that occurs as a result of a copy number loss
is generally termed a ‘deletion LOH’, whereas LOH gener-
ated by an isolated recombinational event is called ‘copy
number-neutral LOH’. Both copy number-neutral LOH
and CNAs that lead to an imbalance in the ratio of parental
alleles from the normal 1:1 constitute regions of allelic im-
balance. When the rate of one or more of these structural
changes increases, a cell is said to exhibit ‘structural
chromosomal instability’ [32]. CNAs and LOH can also be
created by alterations in the number of whole chromo-
somes as a result of errors in the segregation of chromo-
somes during mitosis. Elevation in the incidence of such
events is termed ‘numerical chromosomal instability’ [32].
Genomic scars as reporters of homologous
recombination deficiency and drug response
A genomic scar can be defined as a genomic aberration
with a known origin. Recent attempts at developing an
assay that acknowledges the different means by which de-
fects in HR may occur besides BRCA1/2 dysfunction have
centered around the measurement of such scars (Table 1)
[29,33-35]. The major challenge in this endeavor has been
to distinguish HR defect (HRD)-related genomic aberra-
tions from the wide-ranging complexity inherent to cancer
genomes. Indeed, the role played by BRCA1 in other DNA
repair mechanisms such as mismatch repair and its role at
stalled replication forks may obfuscate any HRD-related
signal [36,37]. On the other hand, spontaneous, chance
events and mutagen-induced changes have no definitive
root in defective HR and yet the scars of these events may
confound the quantification of a bona fide HRD. Further-
more, numerical chromosomal instability and one-off
events such as whole-genome duplications and a newly
described phenomenon known as ‘chromothripsis’ can all
prevent the accurate measurement of HRD-related scars
[32]. Chromothripsis, which is a single chromosomal
shattering event followed by reconstitution of the genomic
fragments, results in localized, complex rearrangements
that, even if they have a basis in a targetable HR deficiency,
can result in an overestimate of the gravity, and hence
exploitability, of the defect [38,39]. In contrast, events that
spatially overlap in such a way that only the effects of one
are countable can lead to an underestimate of the extent of
genomic instability [29]. In cases in which matched gen-
omic germline data are unavailable, germline copy numbervariants and germline runs of homozygosity can confound
CNA- and LOH-based measures of scarring, respectively.
On account of these issues, recent research has taken
advantage of the allelic information and mutational context
afforded by advances in single-nucleotide polymorphism
(SNP) microarray and high-throughput sequencing tech-
nologies, respectively, and several measures of scarring
believed to report an HRD have been developed.Structural chromosomal instability scars from microarrays
By training a classifier on bacterial artificial chromosome and
oligonucleotide array comparative genomic hybridization
(aCGH) data from BRCA1/2 germline mutation status-
annotated breast cancer data sets, several studies have
demonstrated the utility of genome-wide information in
identifying HR-defective tumors, which they also linked to
better platinum response rates [40-42]. In general, these
studies found that BRCA1 and BRCA2 germline-mutated
cancers harbored a greater number of break points and
hence copy number changes. In two studies of independent
TNBC cohorts, these aCGH classifiers exhibited a sensitiv-
ity of approximately 80% in defining samples with BRCA1
mutation [40,42]. However, in comparison with newer SNP
microarray technology, aCGH presents a number of limita-
tions, which make it more difficult to discriminate between
HRD-related genomic changes and the many confounding
alterations that can affect the genome, leading to poorer
specificity. Specifically, the information from SNP micro-
array platforms makes it possible to distinguish between
inherited copy number changes due to normal cell contam-
ination and acquired DNA repair defect-related changes in
cancer cells, an ability that is notably absent from aCGH
analyses. Moreover, as one study described below demon-
strates, the capacity to estimate tumor ploidy status from
SNP microarray data - again a feature absent from aCGH
data - may have implications for predicting platinum
treatment outcome [35].
Capitalizing on these advantages, Birkbak and colleagues
[33] used SNP microarray data to test their hypothesis that
the aberrant chromosomal structures formed as a result of
defective HR are likely to be resolved with allelic imbalance
extending from the double-strand break point to the
subtelomeres of a chromosome. By scoring tumors for the
frequency with which these types of genomic segment
occurred, they extracted a telomeric allelic imbalance score
(NtAi) (Figure 2 and Table 1) [33], which ranges from 0 to
46, with 2 being the maximum permissible contribution by
each chromosome. High levels of NtAi were shown to
predict sensitivity to platinum agents in breast cancer cell
lines, HGSCs and TNBCs. Moreover, tumors with muta-
tion, promoter methylation, or low levels of mRNA for ei-
ther BRCA1 or BRCA2 were demonstrated to have a higher
burden of NtAi than tumors without BRCA1/2 deficiency.
Table 1 Genomic scars of homologous recombination deficiency and relationships to drug response
Input Name Demonstrated objective(s) Output Data sets used (sample size) References
Segmented allele-specific copy
number from SNP microarray data
Telomeric allelic imbalance
score (NtAi)
1. Indicate sensitivity to
platinum drugs
Integer between 0 and 46
per sample
Breast cancer cell lines (10 + 24) [33,45]
2. Indicate BRCA1/2
dysfunction
Cisplatin-1 TNBC trial (27)




1. Indicate HR dysfunction Integer from 0 upper sample MDACC ovarian cancers (152) [29,44,45]
2. Indicate sensitivity to
platinum drugs
UPMC ovarian cancers (152)
TCGA ovarian cancers (435)
Cancer cell lines (57)
Cisplatin-1 TNBC trial (27)
Cisplatin-2 TNBC trial (37)
PreECOG TNBC/BRCA1/2 trial (80)
Large-scale transition (LST)
score
1. Indicate HR dysfunction Integer from 0 upper sample BLBC discovery set (65) [35,45]
2. Indicate sensitivity to
platinum drugs
BLBC validation set (55)
BLBC cell lines (17)
Cisplatin-1 TNBC trial (27)
Cisplatin-2 TNBC trial (37)
LOH clustering 1. Indicate sensitivity to
platinum drugs
Three clusters of tumors: HiA, Boston HGSCs (47) [34]
2. Indicate BRCA1/2
dysfunction






from exome sequencing data




1. Indicate sensitivity to
platinum drugs
















Initial breast cancer data set (21) [1,47]
Larger breast cancer data set (879)
AOCS, Australian Ovarian Cancer Study; BLBC, basal-like breast cancer; HGSC, high-grade serous ovarian cancer; HR, homologous recombination; LOH, loss of heterozygosity; MDACC, MD Anderson Cancer Center; Nmut,














Figure 2 Scoring by genomic scars of homologous recombination deficiency and drug response. Eight examples of various forms of structural
copy number aberrations and rearrangements are given, whereby each box, lettered A to F, represents a genomic segment of approximately 3 Mbp in
length. Below the chromosomes, the three genomic scars - homologous recombination defect (HRD), telomeric allelic imbalance score (NtAi), and
large-scale transition (LST) - are listed along with the respective integer count for the scar (0 = not seen, 1 = detected once). LOH, loss of heterozygosity.
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clustering HGSCs according to significantly frequent re-
gions of LOH produces three platinum response-linked
groups of tumors: one harboring comparatively little LOH
(Lo cluster) and two possessing high levels of LOH: the
HiA and HiB clusters, distinguished by the presence and
absence of 13q chromosomal loss and more frequent LOH
on 5q and 17, respectively (Table 1). When the platinum
response data available for three independent HGSC data
sets were used, patients in the HiA cluster were found to
have lower rates of resistance. In contrast, the rate of resist-
ance was higher for the HiB and Lo clusters. Application of
this LOH clustering approach to a high-grade breast cancer
data set separated tumors into a Lo cluster comprising
HER2- and hormone receptor-positive cancers and a Hi
cluster comprising TNBCs and BRCA1-associated tumors.
However, the relevance of the HiA-versus-HiB distinction
to TNBC has yet to be investigated.
Leveraging on the known association between BRCA1/2
deficiency and response to DNA damage-inducing drugs
[21,43], Abkevich and colleagues [29], of Myriad Genetics
Inc. (Salt Lake City, UT, USA), developed an HRD score
defined as the number of subchromosomal segments(excluding chromosome 17) with LOH of a size exceeding
15 Mbp but shorter than the length of a complete chromo-
some (Figure 2 and Table 1). The objective of this score
was to provide a comprehensive means of assessing defects
in HR beyond sequencing of BRCA1 and BRCA2. To evalu-
ate the correlation between HRD score and HR deficiency,
three independent HGSC cohorts along with 57 cancer cell
lines were assessed for bi-allelic functional inactivation of
BRCA1, BRCA2, or RAD51C through the integration of
mutation, methylation, expression, and LOH data. The
presence of bi-allelic inactivation of these genes was taken
as a surrogate for HR deficiency. In all data sets, HRD score
was elevated in HR-deficient samples, which stood in con-
trast to measures of whole chromosomal LOH and LOH of
regions of less than 15 Mbp in length, suggesting that the
maximum and minimum size thresholds employed were
able to filter out aberrations because of numerical chromo-
somal instability and short non-HRD-related aberrations,
respectively. Furthermore, in the phase II PrECOG 0105
study of gemcitabine and carboplatin plus iniparib (BSI-
201) as neoadjuvant therapy for TNBC and BRCA1/2
mutation-associated breast cancer, 70% of patients with an
HRD score of more than 9 responded compared with 20%
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that HRD score was significantly correlated with pathologic
response. This association remained significant when pa-
tients with known BRCA1 or BRCA2 were excluded from
the analysis [44]. Besides breast and ovarian cancers, HRD
scores above 9 were characteristic for HR deficiency and
were also observed in esophagus, lung, and prostate tumors
as well as gastric, colon, and brain cell lines, advancing the
case that HRD score has general applicability to distinct
cancer types.
A separate signature of chromosomal instability, termed
‘large-scale transitions’ (LSTs), was established by using
basal-like breast cancer and cell line data sets in which
samples with BRCA1 promoter methylation or BRCA1/2
mutation (germline or somatic) were considered BRCA1/2-
inactive [35]. For this genomic scar, copy number variant
regions shorter than 3 Mb are first filtered and smoothed.
This is followed by a count of the number of break points
that occur between regions of at least 10 Mb in length for
each chromosomal arm of a sample, with the sample’s LST
score being the sum of these counts (Figure 2 and Table 1).
After genomic ploidy was estimated on the basis of SNP-
based microarray data, near-diploid tumors were classified
as BRCA1/2-deficient if the number of LSTs exceeded
15. In near-tetraploid tumors, an LST cutoff value of 20
was used to segregate tumors into BRCA1/2-intact and
BRCA1/2-deficient. The LST measure of HRD-related
genomic scarring and its associated cutoff were found to
significantly indicate BRCA1/2 deficiency in an independ-
ent validation data set of basal-like breast cancers as well as
basal-like breast cancer cell lines.
Recently, it has been shown that HRD, NtAi, and LST are
highly correlated with each other and with BRCA1/2
deficiency (BRCA1 promoter methylation, germline, or
somatic) in a breast cancer cohort that encompassed all the
molecularly defined subtypes. Among TNBCs, all three
scores were associated with cisplatin sensitivity [45].
Furthermore, the arithmetic mean of the three scores was
even more strongly associated with BRCA1/2 deficiency
and therapeutic response.Sequencing-based mutational signatures
The advent of massively parallel sequencing has enabled the
mutational effects of a diverse range of etiological drivers to
be unraveled. By finding the total number of somatic
synonymous and non-synonymous mutations (Nmut) in the
exome of each ovarian tumor in a cohort of 316, Birkbak
and colleagues [46] found Nmut to be higher among
patients who responded well to chemotherapy (platinum
agent with or without taxane) than among those who failed
to respond (Table 1). Moreover, higher Nmut was observed
in patients with germline or somatic BRCA1/2 mutation.
Interestingly, within the 70 ovarian tumors harboring eithergermline or somatic BRCA1/2 mutation, cases that were
considered chemotherapy-sensitive possessed a higher mu-
tational burden than cases that were considered resistant,
whereas in the wild-type BRCA1/2 population, this
association was not observed.
In contrast to the integer scores that Nmut and three of
the SNP microarray-based scars provide, several sequence-
based studies have concentrated on examining the specific
type and pattern of mutations that certain genomic events
leave in their wake. In the first study to use mutational
context to mathematically extract signatures of mutational
processes, Nik-Zainal and colleagues [47] catalogued somat-
ically acquired mutational signatures in 21 deep-sequenced
breast cancers (Table 1). These included eight TNBCs, of
which five possessed germline mutation and heterozygous
loss of BRCA1, and four non-TNBC tumors with BRCA2
germline mutation and heterozygous loss. Interrogating the
bases either side of each substitution to give a trinucleotide
sequence context comprising 96 possible combinations
followed by non-negative matrix factorization, the authors
were able to decompose the spectrum of sequence contexts
into five signatures (‘signatures A-E’) each believed to
represent the scar of a distinct mutational process [1].
Hierarchical clustering of the relative contributions of these
signatures to the mutational catalogue of each breast cancer
revealed ‘signature A’ and ‘signature D’, representing a lesser
and greater proportion of the total signature contribution,
respectively, in BRCA1/2-associated tumors than in
BRCA1/2 wild-type tumors. Whereas ‘signature A’ exhibited
enrichment for C >T conversions at XpCpG trinucleotides,
‘signature D’ displayed a relatively even distribution of
mutations across the 96 trinucleotides. During investigation
of the patterns of indels in the 21 tumors, two further
hallmarks of BRCA1/2 mutation were ascertained. The first
was the observation that the size of indels was typically
greater in BRCA1/2-inactivated cancers. The second
hallmark required the authors to examine whether the
sequences flanking each indel were either short tandem re-
peats or short homologous sequences. BRCA1/2-inactivated
tumors were differentiated from BRCA1/2-intact tumors
by having a greater frequency of short homologous
sequences adjoining indels. This observation is congruent
with the notion of error-prone non-homologous end joining
compensating for defective HR since such short homology-
flanked indels would facilitate the joining of two non-
homologous sequences through processes such as
micro-homology single-strand annealing.
Following this seminal work, the repertoire of mutational
signatures across 30 different cancer types was examined,
and a further 16 substitution-based mutational signatures
were identified (Table 1) [1]. The BRCA1/2 defect-
associated mutational signature D was relabeled ‘signature
3’ and was seen to be exclusively over-represented in breast,
ovarian, and pancreatic cancers for which germline
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risk. Among breast tumors in the study, ‘signature 3’ was
found to be operative in 255 out of 879 cases, which ex-
ceeds the estimated 5% to 10% of breast cancers accounted
for by BRCA1/2-mutated tumors [48], supporting the case
that ‘signature 3’ captures the effects of HR deficiencies at-
tributable to a variety of means of BRCA1/2 inactivation as
well as abnormalities in the function of other genes associ-
ated with HR.
The companion diagnostic challenge
The development of biomarkers that accurately and
robustly predict treatment outcome is a key part of the
drive toward personalized medicine. Already one prospect-
ive clinical trial is under way to establish HRD score forFigure 3 Workflow for the development of an integrated predictive b
directed therapy. The workflow begins with genomics data - either seque
samples that have been annotated with patient response data to a given H
measure and a cutoff with high negative predictive value (NPV) were show
(PPV) due to inclusion of patients who have developed resistance (for exam
groups can be identified: those predicted not to respond and those predic
should not be treated with the drug, whereas for patients in the predicted
Within the latter group, a biomarker excluding those with acquired resistan
dichotomizing patients into those who do and those who do not benefit.
biomarker, the resultant two-step companion diagnostic should possess boselecting appropriate patients with ovarian cancer for treat-
ment with the PARP inhibitor, rucaparib (ClinicalTrials.gov
ID: NCT01891344), and equivalent studies will be carried
out as exploratory analyses in TNBCs or BRCA1/2-related
breast cancers. Moreover, despite the sensitivity with which
the genomic scars discussed predict inactivation of genes
involved in HR, limitations exist to the application of these
assays as a companion diagnostic for drugs that target
HRDs. Unlike gene expression, which is liable to the influ-
ence of many confounding variables, genomic scars offer a
comparatively stable readout of a tumor’s lifetime DNA
damage repair competency, including the impact of HR
inactivation where constructed to do so. Consequently,
similar to other biomarkers such as estrogen receptor
testing as a companion diagnostic for hormonal therapy,iomarker of response to homologous recombination (HR) defect
nce or single-nucleotide polymorphism microarray data - for tumor
R targeting drug therapy. After development of a genomic scar
n to identify non-responders but likely poor positive predictive value
ple, 53BP1 loss) subsequent to development of the genomic scar, two
ted to respond accepting a poor PPV. Patients in the former group
responder group, gene expression or mutation data are collected.
ce is constructed that is highly specific for response to the drug, better
By combining the genomic scar biomarker with the resistance-refined
th high NPV and high PPV.
Note: This article is part of a series on ‘Recent advances in
breast cancer treatment’, edited by Jenny Chang. Other
articles in this series can be found at http://breast-cancer-
research.com/series/treatment.
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predictive value (NPV) biomarkers of response to HR
deficiency-targeting drugs, meaning that the great majority
of patients who test negative for the biomarker will not
benefit from the therapy. However, the relative stability of
genomic scars is also their weakness. By chronicling the
past but not documenting the present, genomic scar
measures report whether or not a defect in HR has been
operative at some point in tumorigenesis and not whether
it remains operative at the point of treatment. A variety of
mechanisms could restore HR or compensate for its loss in
the aftermath of genomic scarring. Loss of 53BP1 [49] and
reversion mutations to BRCA1 and BRCA2 [50-53] have
both been demonstrated to confer resistance to platinum
agents and PARP inhibitors through the restoration of HR.
Pathways that operate independently of repair processes,
such as drug catabolism and transporter activity, may also
grant resistance [54]. To add further complexity to the
issue, one study has found that upregulated activity of the
c-MYC oncoprotein induces resistance to cisplatin medi-
ated by regulation of PARP1-interacting genes [55]. Conse-
quently, genomic scarring measures are likely to have
relatively low positive predictive values (PPVs) with the
consequence that a substantial number of patients who
would not benefit from platinum-based agents and PARP
inhibitors would be predicted to do so. Thus, although the
argument for using genomic scars as a companion diagnos-
tic may be sustainable on the basis that platinum-based
agents either are the standard of care (in ovarian cancer) or
have a toxicity profile at least comparable to that of stand-
ard alternatives (in breast cancer), the development of a
biomarker that possesses both high NPV and PPV repre-
sents an optimal and achievable objective.
To address this, the development of a genomic scar-
based predictive biomarker could be followed by the
construction of a second biomarker by using only the
population for which the genomic scar predicts drug effi-
cacy (Figure 3). By looking within a genomic scar-predicted
responder population, the signal from resistance mecha-
nisms that specifically operate within a HR-deficient setting
should be stronger than if the population was taken as a
whole. Mutational data could reveal reversions in a suite of
HR-related genes, whereas transcriptional data might
uncover the elevated expression of genes that compensate
for HR impairment. Coupling the high-NPV genomic scar
biomarker with a high-PPV post-genomic scar biomarker
into an integrated biomarker would thus capture the best
of both approaches (Figure 3).
Conclusions
Although targeting DNA repair deficiencies in cancer has
been a mainstay of the therapeutic oncology armamentar-
ium for decades, this has been more through serendipity
and observation of average effects in populations thanby mechanistic DNA repair activity-informed design.
Consequently, the approach has lacked a personalized
medicine companion diagnostic strategy. Consistent with
the requirement of the US Food and Drug Administration
for every new drug to be accompanied to market by a
biomarker that predicts its effectiveness, the rapidity with
which PARP inhibitors and now genomic scars have been
brought from concept to clinical trial reflects the current
interest in selecting patients for whom administration of a
drug that impacts the DNA damage response is predicted
to be clinically beneficial. However, therapies directed at
HRDs are not the only examples of therapy that could be
individualized by using genomic scar-based biomarkers.
Any flaw in the genomic maintenance machinery that (a)
can be capitalized on therapeutically and (b) leaves an
imprint in the genome that is detectable through current
techniques and technologies is ripe for the development of
a genomic scar to predict drug response. In compiling a list
of 21 validated mutational signatures, researchers have
already taken the first steps toward the goal of constructing
a repertoire of integrated predictive biomarkers [1]. One
example outside the context of HR deficiency is that of
Alexandrov and colleagues’ ‘Signature 6’ [1], which was
found to be associated with a defect in DNA mismatch
repair. Such a signature may in turn predict the effective-
ness of drugs like methotrexate, which has been shown to
be selectively effective in mismatch repair-deficient cancer
cells [56]. The next steps therefore will require the
characterization of the etiologies behind every one of these
signatures and, in the case of SNP microarray-based scars,
the expansion of our understanding of the interaction
between the scar repertoire and the presence of other
targetable deficiencies in the DNA maintenance machinery.Abbreviations
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